Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
News May 06, 2014
Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).
Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms were not disclosed.
Extra-Resistant Wheat is Created From New Gene CombinationNews
A new combination of different strains of resistant wheat may help farmers avoid a common fungal disease.READ MORE
Barrier to Liquid Biopsies Overcome with Blood Stabilization TechniqueNews
A new technique that prolongs the lifespan of blood samples could be a breakthrough for liquid biopsy assays.READ MORE